Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA cardiology

• Publication date

  2017-12-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamacardio.2017.4228PMID 29214305PMCID PMC6594440
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Net reclassification index at event rate: properties and relationships

  2017cited by this paper
• Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

  2016cited by this paper
• Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study

  2016cited by this paper
• Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

  2015cited by this paper
• Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review.

  2015cited by this paper
• Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis

  2015cited by this paper
• Tests of calibration and goodness‐of‐fit in the survival setting

  2015cited by this paper
• Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

  2015cited by this paper
• 9. Microvascular Complications and Foot Care

  2015cited by this paper
• Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.

  2015cited by this paper
• 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials

  2015cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

  2015cited by this paper
• Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Review of Cardiovascular Literature

  2014cited by this paper
• Standards of Medical Care in Diabetes—2015: Summary of Revisions

  2014cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

  2014cited by this paper
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

  2014cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus

  2013cited by this paper
• Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study.

  2012cited by this paper
• Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

  2012cited by this paper
• Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

  2012cited by this paper
• Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.

  2012cited by this paper
• A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus

  2012cited by this paper
• Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.

  2012cited by this paper
• Interpreting incremental value of markers added to risk prediction models.

  2012cited by this paper
• Temporal trends in the prevalence of diabetic kidney disease in the United States.

  2011cited by this paper
• High-normal albuminuria and risk of heart failure in the community.

  2011cited by this paper
• Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

  2011cited by this paper
• Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.

  2011cited by this paper
• The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

  2011cited by this paper
• Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

  2010cited by this paper
• Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure: Data From the GISSI-Heart Failure Trial

  2010cited by this paper
• Albuminuria in chronic heart failure: prevalence and prognostic importance.

  2009cited by this paper
• N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy

  2006cited by this paper
• Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes.

  2004cited by this paper
• Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.

  2003cited by this paper
• Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

  2001cited by this paper
• Regression modelling strategies for improved prognostic prediction.

  1984cited by this paper

• Diabetic kidney disease, biomarkers, and finerenone.

  2026cites this paper
• Renin-Independent Aldosteronism Heightened the Risk of Renal Impairment in Chinese Adults from Hakka Biobank

  2026cites this paper
• Association of insulin resistance indices with major adverse cardiovascular events in patients with acute myocardial infarction and chronic Kidney disease: a retrospective cohort study

  2026cites this paper
• Albuminuria is associated with worse outcomes in non‐diabetics hospitalized with acute heart failure

  2025cites this paper
• Sex differences in the prognostic value of urinary albumin-to-creatinine ratio for coronary artery disease and cardiovascular events in people with type 2 diabetes and normoalbuminuria

  2025cites this paper
• Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024

  2025cites this paper
• Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes

  2025cites this paper
• Diabetic Kidney Disease Update

  2025cites this paper
• Microalbuminuria Predicts Elevated Right Ventricular Filling Pressure in Non-Obstructive Coronary Artery Disease

  2025cites this paper
• Diabetic kidney disease phenotypes and the risk of cardiovascular events: The Silesia Diabetes-Heart Project

  2025cites this paper
• Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level pooled analysis from CANVAS Program and CREDENCE trial.

  2025cites this paper
• Association of MTHFR A1298C polymorphism and blood homocysteine levels with proteinuria in patients with type 2 diabetes mellitus

  2025cites this paper
• Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials

  2025cites this paper
• Association of Left Atrium Remodeling With Major Adverse Cardiovascular Events in Asymptomatic Type 2 Diabetes Patients With Early Chronic Kidney Disease

  2025cites this paper
• Quantification of Cardiovascular Disease Risk Among Hypertensive Subjects in Active Romanian Population Using New Echocardiographic, Biological and Atherogenic Markers

  2025cites this paper
• Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.

  2025cites this paper
• Prospective Study on Kidney Dysfunction Markers and Risk for Mortality among South Asians

  2024cites this paper
• Interaction of proteinuria and diabetes on the risk of cardiovascular events: a prospective cohort CKD-ROUTE study

  2024cites this paper
• Good metabolic control is associated with decreased circulating factor VIIa– antithrombin complexes in type 2 diabetes: a cross-sectional study

  2024cites this paper
• Prevalence and Risk Factors of Chronic Kidney Disease in Patients With Type 2 Diabetes in China: Cross-Sectional Study

  2024cites this paper
• Joint effects of physical frailty and traditional cardiovascular risk factor control on cardiovascular disease in patients with diabetes

  2024cites this paper
• Comprehensive analysis of cuproptosis-related ceRNA network and immune infiltration in diabetic kidney disease

  2024cites this paper
• Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis

  2024cites this paper
• Альбумін-креатинінове співвідношення у сечі: діагностичне та прогностичне значення щодо уражень нирок за умов артеріальної гіпертензії та цукрового діабету 2-го типу (огляд літератури)

  2024cites this paper
• Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant‐level pooled analysis from the CANVAS Program and CREDENCE trial

  2024cites this paper
• Predictors of High Cardiovascular Risk Among Nonobese Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease in a Chinese Population

  2024cites this paper
• An elevated urinary albumin-to-creatinine ratio increases the risk of incident cardia-cerebrovascular disease in individuals with type 2 diabetes

  2024cites this paper
• Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis

  2024cites this paper
• Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

  2023cites this paper
• Association of Body Weight Time in Target Range With the Risk of Kidney Outcomes in Patients With Overweight/Obesity and Type 2 Diabetes Mellitus.

  2023cites this paper
• Impact of percutaneous coronary intervention on renal function in patients with coronary heart disease.

  2023cites this paper
• Fulfillment and Validity of the Kidney Health Evaluation Measure for People with Diabetes

  2023cites this paper
• Elevated urine albumin creatinine ratio increases cardiovascular mortality in coronary artery disease patients with or without type 2 diabetes mellitus: a multicenter retrospective study

  2023cites this paper
• Joint association of loneliness and traditional risk factor control and incident cardiovascular disease in diabetes patients.

  2023cites this paper
• The Bidirectional Association of Chronic Kidney Disease, Type 2 Diabetes, Atherosclerotic Cardiovascular Disease, and Heart Failure: The Cardio–Renal–Metabolic Syndrome

  2023cites this paper
• The correlation of serum musclin with diabetic nephropathy.

  2023cites this paper
• Precision Prognostics for Cardiovascular Disease in Type 2 Diabetes: A Systematic Review and Meta-analysis

  2023cites this paper
• Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease

  2023cites this paper
• Impact of albuminuria on the various causes of death in diabetic patients: a nationwide population-based study

  2023cites this paper
• Identification of key immune‐related genes and immune infiltration in diabetic nephropathy based on machine learning algorithms

  2023cites this paper
• Albuminuria and Heart Failure: JACC State-of-the-Art Review.

  2023cites this paper
• A Comprehensive Weighted Gene Co-expression Network Analysis Uncovers Potential Targets in Diabetic Kidney Disease

  2022cites this paper
• Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria: Data from subgroup analysis and data on moderate albuminuria

  2022cites this paper
• Retrospective evaluation of microalbuminuria and GFR levels of diabetic patients taking DPP-4 Inhibitor, GLP-1 Analog, or SGLT-2 Inhibitor

  2022cites this paper
• Bidirectional relations between depression symptoms and chronic kidney disease.

  2022cites this paper
• Association of ambulatory blood pressure with coronary microvascular and cardiac dysfunction in asymptomatic type 2 diabetes

  2022cites this paper
• Effect of Glucagon-like Peptide 1 Receptor Agonists on the Renal Protection in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

  2022cites this paper
• Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria

  2022cites this paper
• Dapagliflozin acutely improves Kidney Function in Type 2 Diabetes Mellitus. The PRECARE Study.

  2022cites this paper
• Solasonine alleviates high glucose‐induced podocyte injury through increasing Nrf2‐medicated inhibition of NLRP3 activation

  2022cites this paper
• Use of Glucose-Lowering Agents in Diabetes and CKD

  2022cites this paper
• Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial

  2022cites this paper
• A comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease

  2022cites this paper
• Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice

  2022cites this paper
• Triglycerides to high-density lipoprotein cholesterol ratio is superior to triglycerides and other lipid ratios as an indicator of increased urinary albumin-to-creatinine ratio in the general population of China: a cross-sectional study

  2021cites this paper
• The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease

  2021cites this paper
• Long-Term Variation in Kidney Function and Its Impact After Acute Myocardial Infarction.

  2021cites this paper
• Choosing Medications for Type 2 Diabetes – What Weighting Should Be Given to Cardiovascular Risk Reduction?

  2021cites this paper
• Optimal threshold of urinary albumin-to-creatinine ratio (UACR) for predicting long-term cardiovascular and noncardiovascular mortality

  2021cites this paper
• Association of Stromal Cell-derived Factor-1 With Diabetic Kidney Disease in Type 2 Diabetic Patients

  2021cites this paper
• DMSO_A_292041 847..856

  2021cites this paper
• The role of urinary albumin-to-creatinine ratio as a biomarker to predict stroke: A meta-analysis and systemic review

  2021influential citation
• Urinary albumin-to-creatinine ratio and the risk of first stroke in Chinese hypertensive patients treated with angiotensin-converting enzyme inhibitors

  2021cites this paper
• Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria.

  2021cites this paper
• Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors

  2021cites this paper
• Subgrouping of Type 2 Diabetes Mellitus Patients Based on Proteinuria and Diabetic Control for Treatment and Follow-Up

  2021cites this paper
• Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

  2021cites this paper
• Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

  2021cites this paper
• Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Two-year longitudinal trajectory patterns of albuminuria and subsequent rates of end-stage kidney disease and all-cause death: a nationwide cohort study of biopsy-proven diabetic kidney disease

  2021cites this paper
• Decreased mortality after long term treatment with DPP-4 inhibitors: A retrospective study of US veterans with type 2 diabetes.

  2021cites this paper
• The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

  2021cites this paper
• Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease

  2021cites this paper
• Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2)

  2021cites this paper
• Serum stromal cell-derived factor-1 levels are associated with diabetic kidney disease in type 2 diabetic patients.

  2021cites this paper
• Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

  2021cites this paper
• Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.

  2021cites this paper
• Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

  2021cites this paper
• The Relationship Between Earlier Onset of Natural Menopause and Elevated Urinary Albumin-Creatinine Ratio in Postmenopausal Chinese Women

  2021cites this paper
• Renoprotective Effects of DPP-4 Inhibitors

  2021cites this paper
• Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects

  2021cites this paper
• A LEADER in the management of type 2 diabetes and cardiorenal disease.

  2020cites this paper
• Urine High-Sensitivity Troponin I Predict Incident Cardiovascular Events in Patients with Diabetes Mellitus

  2020cites this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cites this paper
• Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy

  2020cites this paper
• Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

  2020cites this paper
• The Potential of Albuminuria as a Biomarker of Diabetic Complications

  2020cites this paper
• Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial

  2020influential citation
• Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial.

  2020cites this paper
• Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes

  2020cites this paper
• Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users

  2020cites this paper
• Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

  2019cites this paper
• Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.

  2019cites this paper
• SGLT2 inhibitors for primary prevention of cardiovascular events

  2019cites this paper
• The longitudinal effect of subclinical hypothyroidism on urine microalbumin-to-urine creatinine ratio in patients with type 2 diabetes mellitus

  2019cites this paper
• Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

  2019cites this paper
• Elevated triglycerides rather than other lipid parameters are associated with increased urinary albumin to creatinine ratio in the general population of China: a report from the REACTION study

  2019cites this paper
• Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

  2019cites this paper
• Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

  2019cites this paper
• New risk prediction model of coronary heart disease in participants with and without diabetes: Assessments of the Framingham risk and Suita scores in 3-year longitudinal database in a Japanese population

  2019cites this paper